Prevalencia, severidad y costes asociados al diagnóstico de pacientes con esteatosis hepática metabólica (EHmet)
Metabolic associated fatty liver disease (MAFLD) is a major public health problem and is currently the most common cause of chronic liver disease in our environment, associated with the parallel increase in the global epidemic of obesity and type 2 diabetes (DM-2). There are hardly any data on the r...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Universidad de Valladolid |
| Repositorio: | UVaDOC. Repositorio Documental de la Universidad de Valladolid |
| OAI Identifier: | oai:uvadoc.uva.es:10324/59897 |
| Acceso en línea: | https://doi.org/10.35376/10324/59897 https://uvadoc.uva.es/handle/10324/59897 |
| Access Level: | acceso abierto |
| Palabra clave: | Esteatosis hepática Liver Hepática Fatty Esteatosis 32 Ciencias Médicas |
| Sumario: | Metabolic associated fatty liver disease (MAFLD) is a major public health problem and is currently the most common cause of chronic liver disease in our environment, associated with the parallel increase in the global epidemic of obesity and type 2 diabetes (DM-2). There are hardly any data on the real prevalence in our environment, the workload in hepatology consultations, severity of the disease, and the expenses derived from the care of these patients. The objectives of the study are to determine the prevalence of MAFLD in the outpatient clinics of University Clinical Hospital of Valladolid (HCUV), to analyze the risk factors associated with its presence and severity, as well as to describe the medical resources used and derived costs. Design: prospective cohort study of patients with suspected chronic liver disease referred to the HCUV. Epidemiological and analytical variables, genetic polymorphisms, as well as the diagnostic methods used and the costs derived from the diagnosis of these patients were analyzed. The prevalence of MAFLD as a cause of chronic liver disease in our consultations was 42.7%, being the most frequent cause of chronic liver disease in our setting. The risk factors associated with MAFLD in our study are obesity, dyslipidemia, arterial hypertension, DM-2 and metabolic syndrome, as well as the genetic polymorphisms of PNPLA3, TNF-alpha and CNR1, which are also associated with more severe forms of the disease. Non-invasive methods allow diagnosis in most patients. Although liver biopsy is still necessary in some cases, it doubles the cost associated with the care of these patients. |
|---|